ArticleProceedings of the National Academy of Sciences of the United States of America1994
MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 71 citations in OpenAlex.
- Targeting the MYCN interaction network in neuroblastoma.Bioscience reports · 2026Review
- Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer.International journal of molecular sciences · 2024Review
- Distinct effects of etoposide on glutamine-addicted neuroblastoma.Cellular and molecular life sciences : CMLS · 2020Article
- Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.BMC cancer · 2019Article
- Cell death-based treatment of neuroblastoma.Cell death & disease · 2018Review
- Review
- MicroRNA-141 and its associated gene FUS modulate proliferation, migration and cisplatin chemosensitivity in neuroblastoma cell lines.Oncology reports · 2016Article
- Molecular and genetic bases of neuroblastoma.International journal of clinical oncology · 2012Review
- A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.Oncotarget · 2012Article
- Episomal amplification of MYCN in a case of medulloblastoma.Virchows Archiv : an international journal of pathology · 2008Article
- Aflatoxin B1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells.Oncogene · 2003Article
- Neuroblastoma tumour genetics: clinical and biological aspects.Journal of clinical pathology · 2001Review
- Article
- DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies.The American journal of pathology · 1998Review
- Association between the rat homologue of CO-029, a metastasis-associated tetraspanin molecule and consumption coagulopathy.The Journal of cell biology · 1998Article
- MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an Oncogene.Pathology oncology research : POR · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amplification of the human N-myc protooncogene, MYCN, is frequently seen either in extrachromosomal double minutes or in homogeneously staining regions of aggressively growing neuroblastomas. MYCN maps to chromosome 2 band p23-24, but homogeneously staining regions have never been observed at this band, suggesting transposition of MYCN during amplification. We have employed fluorescence in situ hybridization to determine the status of MYCN at 2p23-24 in five human neuroblastoma cell lines. All five lines carried, in addition to amplified MYCN in homogeneously staining regions or double minutes, single-copy MYCN at the normal position. In one line there was coamplification of MYCN together with DNA of the host chromosome 12, to which MYCN had been transposed. Our results suggest a model of amplification where MYCN is retained at its original location. They further sustain the view that either the initial events of MYCN amplification or the further evolution of amplified MYCN copies follow mechanisms different from those leading to amplification of drug-resistance genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.